Der Kaninchen Polyklonal anti-FLT3 Antikörper (ABIN7220672) detektiert spezifisch FLT3 in WB und ELISA.
Dieser Antikörper reagiert spezifisch mit Proben aus Human und Maus.
FLT3
Reaktivität: Human
FACS
Wirt: Maus
Monoclonal
BV10A4
FITC
Applikationshinweise
Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000,ELISA 1:10000,Not yet tested in other applications.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C
Informationen zur Lagerung
Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Haltbarkeit
12 months
Target
FLT3
(Fms-Related tyrosine Kinase 3 (FLT3))
Andere Bezeichnung
Flt-3
Hintergrund
FLT3, CD135, FLK2, STK1, Receptor-type tyrosine-protein kinase FLT3, FL cytokine receptor, Fetal liver kinase-2, FLK-2, Fms-like tyrosine kinase 3, FLT-3, Stem cell tyrosine kinase 1, STK-1, CD antigen CD135FLT3 encodes a class III receptor tyrosine kinase that regulates hematopoiesis. This receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.